Levi & Korsinsky has started an investigation into Biogen Inc. following the failure of its CELIA trial for the BIIB080 Alzheimer's drug, which did not meet its primary endpoint. This led to a sharp decline in Biogen's stock as investors reassessed the company's near-term pipeline value. The investigation focuses on potential violations of federal securities laws related to the company's prior optimistic statements about its drug pipeline. Investors who suffered losses may seek recovery under these laws.
More than 50 companies are actively developing over 55 new drugs for pulmonary arterial hypertension (PAH), a serious lung-related heart condition. These drugs are in various clinical trial stages, with several in late-stage development, aiming to im...
Biogen's shares fell 6.4% on May 14, 2026, after the company announced that its Phase 2 CELIA trial for the drug diranersen failed to meet the primary dose-response endpoint related to clinical dementia rating at Week 76. Despite the setback, Biogen ...
Biogen's stock dropped 6.4% on May 14, 2026, following the release of Phase 2 CELIA trial data showing that diranersen failed to meet its primary dose-response endpoint. Despite this setback, Biogen plans to continue developing diranersen based on po...
Levi & Korsinsky has launched an investigation into Biogen Inc. following a significant stock drop after the CELIA trial for BIIB080 in early Alzheimer's disease failed to meet its primary endpoint. The trial's lack of statistical significance led to...
Biogen Inc. was upgraded from Sell to Hold following its $5.6 billion acquisition of Apellis, which adds near-term revenue and expands its kidney disease portfolio. While multiple sclerosis revenues remain stable, long-term decline is expected, and n...
